​

Funding Round

Series B - Beacon Therapeutics

Series B - Beacon Therapeutics

Investment Firm

Overview

Beacon Therapeutics is an ophthalmic gene therapy company to treat blinding retinal illnesses and restore and enhance eyesight.

Announced Date

Jun 03, 2024

Funding Type

Series B

Highlights

Location

Europe

Social

N/A

Investor Lead

Forbion Capital Partners

Forbion Capital Partners

Forbion Capital Partners is a early_stage_venture and post_ipo and seed firm.

Participant Investors

6

Investor Name
Participant InvestorSyncona Partners LLP
Participant InvestorTCG Crossover
Participant InvestorOxford Science Enterprises
Participant InvestorAdvent Life Sciences
Participant InvestorUniversity of Oxford

Round Details and Background

Beacon Therapeutics raised $170000000 on 2024-06-03 in Series B

Beacon Therapeutics is an ophthalmic gene therapy company to treat blinding retinal illnesses and restore and enhance eyesight.

Company Funding History

2

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jun 12, 2023
Series A - Beacon Therapeutics
2-120.1M
Jun 03, 2024
Series B - Beacon Therapeutics
6-170.0M

Recent Activity

There is no recent news or activity for this profile.